格隆汇10月23日丨卫宁健康(300253.SZ)在互动平台表示，截至目前，公司未直接或间接参与投资沐曦 股份。合作方面，公司近日联合沐曦发布了为医生打造的专属AI桌面工作站WiNBOT。 ...

证券日报网讯卫宁健康（300253）10月21日在互动平台回答投资者提问时表示，截至2025年10月20日， 公司股东户数为113，550户。 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Viewpoints - The report emphasizes the continuous recommendation of domestic investment opportunities due to increasing external technology controls and the ongoing promotion of domestic innovation policies, indicating a clear trend towards self-sufficiency in key technologies [6][13] - The performance of leading domestic computing companies is showing significant revenue growth, validating the trend of domestic industrial development [7][14] Summary by Sections Weekly Perspective - The report highlights the sustained recommendation of domestic investment opportunities, noting a decline in the CSI 300 index by 2.22% and a 5.61% drop in the computer index during the week of October 13-17, 2025 [5][12] Company Dynamics - Haiguang Information reported a revenue of 40.26 billion yuan for Q3 2025, marking a year-on-year growth of 69.60% and a net profit of 759.99 million yuan, up 13.04% [16] - Cambricon Technologies achieved a revenue of 1.727 billion yuan in Q3 2025, with a staggering year-on-year increase of 1332.52%, and a net profit of 567 million yuan, indicating a strong turnaround [14] Investment Recommendations - Key domestic software companies recommended include Kingsoft Office, Dameng Data, and others, while leading domestic computing companies such as Haiguang Information and Sugon are also highlighted for their growth potential [8][15]

证券日报网讯 10月16日晚间，卫宁健康发布公告称，选举刘宁先生担任公司第六届董事会职工代表董 事。 （文章来源：证券日报） ...

每经AI快讯，卫宁健康（SZ 300253，收盘价：8.83元）10月16日晚间发布公告称，公司第六届第十八 次董事会会议于2025年10月15日在公司会议室以现场和通讯相结合的表决方式召开。会议审议了《关于 补选公司第六届董事会薪酬与考核委员会委员的议案》等文件。 每经头条（nbdtoutiao）——"短板"正在被一块块补上！直击湾芯展："中国芯"是怎么炼成的 （记者 王晓波） 2025年1至6月份，卫宁健康的营业收入构成为：医疗卫生信息化行业占比92.54%，互联网医疗健康行 业占比7.46%。 截至发稿，卫宁健康市值为196亿元。 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-078 同意豁免公司第六届董事会第十八次会议的通知期限，并于 2025 年 10 月 15 日召开第六届董事会第十八次会议。 二、会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关 于选举公司第六届董事会副董事长的议案》。 同意选举职工代表董事刘宁先生为公司第六届董事会副董事长， 任期自本次会议审议通过之日起至第六届董事会届满之日止。 三、会议以 7 票同意、0 票反对、0 票弃权的结果审议通过了《关 于补选公司第六届董事会提名委员会委员的议案》。 同意补选职工代表董事刘宁先生为公司第六届董事会提名委员 会委员，任期自本次会议审议通过之日起至第六届董事会届满之日 止。 卫宁健康科技集团股份有限公司 第六届董事会第十八次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 卫宁健康科技集团股份有限公司（以下简称"公司"）于 2025 年10月 15日在公司会议室以现场和通讯相结合的表决方式召开了第 六届董事会第十八次会议。会议通知经全体董事同意，豁免通知时限 的要求，以电话、口头 ...

证券代码：300253 证券简称：卫宁健康 公告编号：2025-079 卫宁健康科技集团股份有限公司 关于非独立董事调整暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、关于非独立董事调整的情况 卫宁健康科技集团股份有限公司（以下简称"公司"）董事会于 近期收到公司第六届董事会非独立董事刘宁先生的书面辞职报告。因 公司治理结构调整，刘宁先生申请辞去公司第六届董事会非独立董事 职务，同时一并辞去董事会提名委员会委员、董事会薪酬与考核委员 会委员职务，辞去上述职务后，刘宁先生将继续在公司担任其他职务。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《公司章程》等规定， 公司于 2025 年 10 月 15 日召开职工代表大会，选举刘宁先生（简历 详见附件）担任公司第六届董事会职工代表董事，任期自本次职工代 表大会选举之日起至公司第六届董事会任期届满之日止。 刘宁先生当选公司职工代表董事后，公司第六届董事会成员不 变，公司董事会中兼任公司高级管理人员职务的董事以及由职工代表 担任的 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Views - The company is increasing its focus on the medical AI sector, accelerating the deployment of AI products [5] - The company's revenue for the first half of 2025 was 839 million yuan, a year-on-year decline of 31.43%, with a net loss of 118 million yuan [5] - The company has adjusted its revenue and profit forecasts for 2025, expecting revenues of 2.725 billion yuan and net profits of 110 million yuan [5] Financial Summary - Total shares outstanding: 2,214.63 million [2] - Market price: 8.81 yuan [2] - Market capitalization: 19,510.87 million yuan [2] - Revenue projections for 2023A to 2027E show fluctuations, with a peak expected in 2027 at 3.176 billion yuan [4] - Net profit projections indicate recovery, with an expected 336 million yuan by 2027 [4] - The company's high-margin software and service revenue accounted for 84.65% of total revenue, up from 73.68% year-on-year [5] - The company has implemented cost-cutting measures, resulting in a 19.07% decrease in sales, management, and R&D expenses [5] AI Product Development - The company is actively enhancing its AI product development, launching the medical large model WinGPT 3.0 and WINEX Copilot 2.2 [5] - These AI products have been deployed in nearly 150 medical institutions, aiding in various medical scenarios [5] - Collaborations with hospitals have been established to enhance AI product capabilities [5]

Core Insights - The company is facing temporary performance pressure due to multiple factors, including deferred customer demand and challenges in new product revenue recognition [1] - The company is increasing its focus on high-margin software and service revenues, which now account for 84.65% of total revenue, up from 73.68% year-on-year [2] - The company is accelerating its AI product development, with significant advancements in medical AI applications and partnerships with various hospitals [3] - Adjustments to revenue and profit forecasts have been made due to macroeconomic changes and increased investment in new product promotion and AI development [4] Financial Performance - For the first half of 2025, the company reported revenue of 839 million yuan, a year-on-year decline of 31.43%, and a net loss of 118 million yuan [1] - The company's high-margin software and technical service revenue reached 710 million yuan, representing a year-on-year increase of 10.97 percentage points in revenue share [2] - Operating expenses, including sales, management, and R&D, decreased by 19.07%, while net cash flow from operating activities increased by 163.44% [2] AI Development - The company is enhancing its AI product development, launching medical models like WinGPT 3.0 and WINEX Copilot 2.2, which are being implemented in nearly 150 medical institutions [3] - Collaborations with hospitals aim to improve AI product capabilities and facilitate deployment across various medical scenarios [3] Investment Outlook - Revenue forecasts for 2025, 2026, and 2027 have been adjusted to 2.725 billion yuan, 2.887 billion yuan, and 3.176 billion yuan, respectively, with net profits of 110 million yuan, 237 million yuan, and 336 million yuan [4] - The company is rated as a "buy" due to the broad development space in the medical information industry and improvements in operational efficiency [4]

上海市广发律师事务所 在本法律意见书中，本所律师根据《股东会规则》的要求，仅就本次股东大 会的召集、召开程序是否合法及是否符合《公司章程》、出席会议人员资格和会 议召集人资格的合法有效性、会议表决程序和表决结果的合法有效性发表意见， 而不对本次股东大会所审议的议案内容和该等议案中所表述的事实或数据的真 实性和准确性发表意见。 关于卫宁健康科技集团股份有限公司 本法律意见书仅供本次股东大会之目的使用，不得被任何人用于其他任何目 的。本所同意，公司可以将本法律意见书作为公司本次股东大会公告材料，随其 他需公告的信息一起向公众披露，本所依法对发表的法律意见承担责任。 本所律师根据相关法律、法规和规范性文件的要求，按照律师行业公认的业 务标准、道德规范和勤勉尽责精神发表意见如下： 一、本次股东大会的召集和召开程序 2025 年第一次临时股东大会的法律意见书 致：卫宁健康科技集团股份有限公司 卫宁健康科技集团股份有限公司（以下简称"公司"）2025 年第一次临时 股东大会于 2025 年 10 月 15 日在上海市静安区寿阳路 99 弄 9 号卫宁健康大厦 16 楼会议室召开。上海市广发律师事务所经公司聘请，委派成赟律 ...